CD44-SLC1A2 gene fusions in gastric cancer. by �씪�꽑�쁺 & �젙�쁽泥�
DOI: 10.1126/scitranslmed.3001423
, 77ra30 (2011);3 Sci Transl Med
 et al.Jiong Tao
 Gene Fusions in Gastric CancerCD44-SLC1A2
 
Editor's Summary
 
 
 
dividing cancer cell may act as a GPS that directs researchers down a new therapeutic avenue for gastric cancer.
of this fusion gene as a drug target or prognostic tool will require more studies, but this particular mistake made by a 
cancer-driving genes, although the protein could also augment other cancer-promoting genetic aberrations. The utility
implication of an overexpressed metabolism-related gene in some gastric tumors may define a new class of 
Most other genes that are fused in cancers encode kinase enzymes or transcriptional regulatory proteins. The
phenotype.
amounts of SLC1A2 than did wild-type cells, suggesting that this aberrant protein may trigger a pro-oncogenic 
 fusion gene had higherCD44-SLC1A2cells. And in a final set of incriminating evidence, tumor cells that sported the 
existed in higher concentrations in gastric cancer cells and cell lines than in normal−−can act as a growth regulator
which−−enhanced these traits. Consistent with the function of SLC1A2 as a transporter of glutamate, the amino acid
and overexpression of the pruned protein−−hallmarks of cancer cells−−dividing and invading soft substrates
yes. Cells in which shortened SLC1A2 expression was silenced with small interfering RNA were less proficient at
the truncated SLC1A2 contributes to gastric cancer development, and their evidence suggested that the answer is 
But an abnormal protein that lives in tumor cells can be an innocent bystander. So, the authors asked whether
cancers created by the authors through overexpression of the fusion gene in normal gastric cells.
inversion. The fusion gene generated a truncated SLC1A2 protein in the original tumors and in a new group of gastric 
, likely the result of a chromosomeCD44probably the strong transcriptional promoter of its neighboring gene, 
 (which encodes a glutamate transporter) to what isSLC1A2/EAAT2chimeric gene fused most of the coding region of 
established gastric tumor cell lines and pinpointed a common breakpoint in three and one, respectively. The resulting 
The authors analyzed copy number variations of genes in more than 100 primary gastric tumors and 27
gastric tumor cells and may contribute to the development of cancer.
cell lung cancers. Now, Tao and her co-workers have documented a fusion gene that forms in a small percentage of
target for therapy. Gene fusions in solid cancers are not so easy to spot, but have been located in prostate and small 
 gene drives chronic myelogenous leukemia and has proven to be a vulnerableBCR-ABLexample, the fused aberrant 
fused to part of another, sometimes forming peculiar hybrid proteins that contribute to the cancer cell phenotype. For
in the process. One result of this chaos is the birth of chimeric genes, wherein one gene segment gets erroneously 
It's ironic, but cancer cells are notoriously bad at cell division, losing bits and rearranging chunks of the genome
Bad Drivers Steer Scientists Toward New Drug Targets
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3Fusion genes are chimeric genes formed in cancers through genomic aberrations such as translocations, am-
plifications, and rearrangements. To identify fusion genes in gastric cancer, we analyzed regions of chromo-
somal imbalance in a cohort of 106 primary gastric cancers and 27 cell lines derived from gastric cancers.
Multiple samples exhibited genomic breakpoints in the 5′ region of SLC1A2/EAAT2, a gene encoding a gluta-
mate transporter. Analysis of a breakpoint-positive SNU16 cell line revealed expression of a CD44-SLC1A2
fusion transcript caused by a paracentric chromosomal inversion, which was predicted to produce a truncated
but functional SLC1A2 protein. In primary tumors, CD44-SLC1A2 gene fusions were detected in 1 to 2% of gas-
tric cancers, but not in adjacent matched normal gastric tissues. When we specifically silenced CD44-SLC1A2,
cellular proliferation, invasion, and anchorage-independent growth were significantly reduced. Conversely,
CD44-SLC1A2 overexpression in gastric cells stimulated these pro-oncogenic traits. CD44-SLC1A2 silencing
caused significant reductions in intracellular glutamate concentrations and sensitized SNU16 cells to cisplatin,
a commonly used chemotherapeutic agent in gastric cancer. We conclude that fusion of the SLC1A2 gene
coding region to CD44 regulatory elements likely causes SLC1A2 transcriptional dysregulation, because tumors
expressing high SLC1A2 levels also tended to be CD44-SLC1A2–positive. CD44-SLC1A2 may represent a class of
gene fusions in cancers that establish a pro-oncogenic metabolic milieu favoring tumor growth and survival.rg
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 INTRODUCTION
Gastric adenocarcinoma, or gastric cancer (GC), is a leading cause of
global cancer mortality, with a 5-year survival rate of ~20% (1, 2). Par-
ticularly prevalent in several Asian countries (3), most GC patients
present with advanced-stage disease, although in Japan and Korea
screening programs with barium photofluorography or endoscopy al-
low earlier detection (4, 5). Current strategies for treating GC patients
are far from optimal, with conventional surgery and chemotherapy reg-
imens conferringmodest survival benefits andmedian survival times of
7 to 10 months (6).
Clinical risk factors for GC include a high-salt diet, Helicobacter
pylori infection, and smoking (2). Although familial patterns of GC
incidence have been reported, most GC cases are sporadic. Studies
investigating the genetic basis of GC have identified germline poly-
morphisms in cytokine genes (for example, interleukin 1b and
TLR4) (7, 8) and mutations in cell junction genes (CDH1) as inherited
GC risk factors (9). In gastric tumors, somatic mutations in oncogenes1Department of Physiology, Yong Loo Lin School of Medicine, National University of
Singapore, 5 Lower Kent Ridge Road, Singapore 119074, Singapore. 2Cancer and Stem Cell
Biology, Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore.
3Cellular and Molecular Research, National Cancer Centre of Singapore, 11 Hospital Drive,
Singapore 169610, Singapore. 4Division of Medical Sciences, National Cancer Centre of
Singapore, Singapore 169610, Singapore. 5Genome Institute of Singapore, 60 Biopolis
Street, Genome02-01, Singapore 138672, Singapore. 6DivisionofMedicalOncology, National
Cancer Centre of Singapore, Singapore 169610, Singapore. 7Department of InternalMedicine,
YonseiCancerCenter, YonseiUniversityCollegeofMedicine, 134Shinchon-Dong, Seodaemun-
Ku, Seoul 120-752, South Korea. 8Department of Medicine and Cancer Center, Howard
University College of Medicine, 2041 Georgia Avenue, Washington, DC 20060, USA. 9Cancer
Science Institute of Singapore, Yong Loo Lin School of Medicine, National University of
Singapore, Singapore 119074, Singapore.
*Present address: Michigan Center for Translational Pathology and Department of
Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
†To whom correspondence should be addressed. E-mail: gmstanp@duke-nus.edu.sg
wwwand tumor suppressor genes such as p53, RUNX3, and b-catenin have
been reported (10–12), along with signature genomic amplifications
(7q, 8p, 17q, and 20q) and deletions (5q, 6p, and 18q) (13). Identifying
additional molecular aberrations in GC could provide further mech-
anistic insights into GC pathogenesis and highlight opportunities for
early detection and new therapies.
Fusion genes are hybrid genes formed by the combination of two
normally separate and distinct genes. In cancers, fusion genes can be
produced by genomic amplifications, translocations, and rearrange-
ments (14), resulting in juxtaposition of oncogenic proteinswith strong
promoters (for example, IgH-Myc) (15) or chimeric proteins with on-
cogenic signaling potential (for example, BCR-ABL) (16). Because of
their cancer-specific nature, fusion genes have the potential to act as
useful diagnostic and therapeutic targets. To date, the vast majority
of cancer-related fusion genes have been identified primarily in hem-
atological malignancies, where they have been used to identify partic-
ular cancer subtypes (for example, PML-RARa in acute promyelocytic
leukemia) and used as drug targets [for example, BCR-ABL in chronic
myelogenous leukemia (CML)] (17, 18).
In contrast to the hematological malignancies, in solid epithelial
cancers, very few fusion genes have been identified. In these cancers,
higher genomic complexity and clonal heterogeneity can confound
standard cytogenetic assays (19). Nevertheless, recent discoveries of
TMPRSS2-ERG in prostate cancer (20) and EML4-ALK in non–small
cell lung cancer (21) have confirmed the existence of recurrent fusion
genes in solid tumors and shown that these can be identified with high-
resolution genomic approaches. Previously, we have used transcrip-
tome sequencing to identify BRAF-related gene fusions in GC,
providing evidence for this important class of molecular aberrations
in gastrointestinal (GI) cancers (22). Here, we adopted an alternative
strategy to discover a recurrent fusion gene in GC..ScienceTranslationalMedicine.org 6 April 2011 Vol 3 Issue 77 77ra30 1
R E S EARCH ART I C L ERESULTS
Analysis of GC copy number alterations identifies
recurrent SLC1A2/EAAT2 genomic breakpoints
We hypothesized that a detailed fine-scale survey of genomic copy
number alterations (CNAs) in GC might reveal potential genes dis-
rupted by fusion events. Using high-density array-based comparative
genomic hybridization (aCGH) microarrays, we profiled a discovery
cohort of 133 GCs (106 primary tumors and 27 cell lines). In a valida-
tion of the aCGH data, we successfully reidentified several previously
described genomic aberrations inGC, including amplifications in c-Myc
(23), HER2 (24), RAB23 (25), and PTEN deletions (26) (fig. S1). Towwwnominate potential fusion genes, we used a technique called genomic
breakpoint analysis (GBA), previously used to identify fusion genes in
leukemia (27). In this strategy, putative chromosomal breakpoints were
identified by examining closely spaced microarray probes displaying
prominent transitions in copy number status, from low to high copy
number or vice versa. Figure 1A provides a representative example of
a genomic breakpoint in the CALCR gene. In total, we identified 99 ge-
nomic breakpoints occurring in genes such as CALCR, PERLD1, and
CKAP5 (table S1).
For most genes exhibiting genomic breakpoints in multiple samples
(for example, CRKRS and TTC25), the breakpoints were randomly scat-
tered throughout the gene body, consistent with a random breakage dur-.ScienceTranslationalMedicine.or
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 ing chromosomal amplification. However,
4 of 133 GCs (three primary tumors and
one cell line—GC980417, GC20021048,
GC2000038, and SNU16) exhibited ge-
nomic breakpoints specifically localized
to the 5′ region of the SLC1A2/EAAT2 gene,
encoding a high-affinity glutamate trans-
porter (hereafter referred to as SLC1A2)
(Fig. 1B). To validate the SLC1A2 break-
point region, we performed fluorescence in
situ hybridization (FISH) analysis using
fosmid probes that mapped upstream or
downstream of the putative breakpoint
(WI2-67O19 andWI2-1928P9). Support-
ing the aCGH data, the WI2-67O19
upstream probe (35384118-35427600) cov-
ering the first exon of SLC1A2 showed
three to four signals in SNU16 nuclei
(Fig. 1C, left), confirming previous stu-
dies that SNU16 is a naturally tetraploid
cell line (28). In contrast, the downstream
WI2-1928P9 probe (35323126-35359663)
located at SLC1A2 intron 1 showed mul-
tiple hybridization signals (>50 copies),
indicating a large amplification event
(Fig. 1C, right).
SLC1A2 breakpoint
characterization reveals
a CD44-SLC1A2 gene fusion
Integrating the SLC1A2 breakpoint re-
gions from the aCGH and the FISH data,
we defined a 15- to 24-kb minimal com-
mon breakpoint window in the SLC1A2
first intron (Fig. 1, B andD, red bar). We
hypothesized that chromosomal aberra-
tions affecting this region might disrupt
the SLC1A2 gene and result in potential
fusion partners. To test this possibility, we
performed 5′ RNA ligase–mediated rap-
id amplification of complementary DNA
(cDNA) ends (RLM-RACE) to character-
ize SLC1A2 transcript sequences upstream
of SLC1A2 exon 2.A 250–base pair (bp) 5′
RACEproductwas identified inbreakpoint-
positive SNU16 cells, but not in otherGCFig. 1. Genomic breakpoint analysis of gastric cancer. (A) Representativeexample of a genomic breakpoint.
aCGH profile of gastric cancer (GC) tumor GC20020700 exhibiting a genomic breakpoint in the CALCR gene
on chromosome 7q12. X axis, physical chromosomal coordinates; y axis, log2-transformed smoothened
values (that is, dotted line at 0 indicates copy number equal to 2). Red arrow, breakpoint of interest; dot,
a microarray probe. (B) Genomic breakpoints in the 5′ region of SLC1A2 in four GCs (three primary tumors
and one cell line: GC2000038, GC980417, GC20021048, and SNU16). Red arrows, breakpoints of interest. (C)
FISH validation of SLC1A2 breakpoints. ProbesWI2-67O19 (red) andWI2-1928P9 (green) cover SLC1A2 exon
1 or intron 1, respectively. (D) Genomic organization of the SLC1A2 gene. Vertical bars represent SLC1A2
exons connected by intervening introns. Total length of the SLC1A2 gene is 168 kb. Red bar, minimal com-
mon recurrent breakpoint region in SLC1A2 intron 1 (15 to 24 kb); black arrow, location of oligonucleotide
primer used for 5′ RLM-RACE analysis.g 6 April 2011 Vol 3 Issue 77 77ra30 2
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 cell lineswithoutSLC1A2breakpoints (AGS,
YCC1, YCC9, andN87) (Fig. 2A). Sequenc-
ing of the amplified SNU16 product re-
vealed a CD44-SLC1A2 fusion transcript,
formed by the juxtaposition of CD44 exon
1 to SLC1A2 exon2 (Fig. 2B).Complemen-
tary to the 5′ RACE analysis, a 3′ RACE
analysis in SNU16 cells that characterized
transcripts downstream of SLC1A2 exon
1 did not identify any additional fusion
partners besides wild-type SLC1A2 tran-
scripts (fig. S2A). To validate the 5′ RACE
results, we designed combination sets of
polymerase chain reaction (PCR) primers
targeting CD44 exon 1 (forward primer)
and SLC1A2 exons 3 to 6 (reverse primers)
to directly detect the fusion by reverse
transcription–PCR(RT-PCR).CD44-SLC1A2
transcripts were detected in SNU16 cells,
but not in other cell lines or in commer-
cially available normal gastric (NG) tissue
(Fig. 2Cand fig. S2B).Weconfirmed expres-
sion of a complete ~1.6-kb CD44-SLC1A2
transcript in SNU16 cells using RT-PCR
primers targetingCD44 exon 1 and SLC1A2
exon 11 (the last SLC1A2 exon) (fig. S2C).
These results demonstrate the existence of
a CD44-SLC1A2 gene fusion in SNU16
cells.
CD44 and SLC1A2 lie adjacent to each
other on chromosome 11p13, being sep-
arated by only ~19 kb (Fig. 2D). The two
genes are transcribed toward each other,
indicating that they have distinct promo-
ters. Because they lie on opposite strands,
it is unlikely that theCD44-SLC1A2 fusion
is caused by a transcriptional readthrough
event (29). We thus hypothesized that
theCD44-SLC1A2 gene fusionmight have
been caused by a paracentric chromosomal
inversion (fig. S3A). Notably, 11p13-15,
where CD44 and SLC1A2 are located, has
been described as a frequent site of genome
rearrangement in gastric and esophageal
cancers (30). Spectral karyotyping (SKY)
analysis confirmed the presence of at least
two 11p13-11p14 genome rearrangements
in SNU16cells: one involving fusionof chro-
mosome 1 with chromosome 11 at band
11p13-14 and the second involving a com-
plex chromosomal scenario with rearrange-
ments joining chromosomes 5, 10, and 11
(fig. S3B).
Weused twodifferent strategies to verify
the presence of CD44/SLC1A2 genomic
inversions in this region. First, we used
fiber-FISH, a high-resolution method for
genomic DNA mapping (31). FosmidFig. 2. CD44-SLC1A2 gene fusions. (A) 5′ SLC1A2 RLM-RACE of GC cell lines. (B) CD44-SLC1A2 fusion se-
quence. Blue, CD44 exon 1; red, SLC1A2 exon 2; underline, ATG sites. (C) CD44-SLC1A2 RT-PCR. Primers were
targeted to CD44 exon 1 (blue arrow) and SLC1A2 exons 3 to 6 (orange arrows). NG, normal stomach; N87,
fusion-negative line. (D) Top: CD44 and SLC1A2 chromosomal organization. Bottom: CD44-SLC1A2 relation-
ship to CD44 and SLC1A2 parent genes. (E) Fiber-FISH. Top: Probe 1 (Rp1-68d18) covers CD44 (3′ of intron 1)
and SLC1A2 (3′ of intron 1). Probe 2 (Rp11-1148l23) covers the 5′ region of SLC1A2 intron 1 and upstream
sequence. Bottom: Fiber-FISH images of control CCL159 cells and fusion-positive SNU16 cells. (F) Long-range
PCR. Primers were targeted to CD44 exon 1 and the SLC1A2 first intron [black arrows in (E)]. SNU16, fusion-
positive; AGS, fusion-negative. Primers are black arrows in (E). (G) Western blot of fusion-positive SNU16 and
fusion-negative AGS and SNU5 cells (membrane fractions). Top: Anti-SLC1A2 antibodies. Bottom: a-Tubulin
antibody control. (H) CD44-SLC1A2 ectopic expression. Top: CD44-SLC1A2 expression construct carrying a
GFP tag. Arrow, promoter. ATG sites in CD44 exon 1 and SLC1A2 exon 2 are shown. Bottom: Immunoblotting
with anti-SLC1A2 antibodies.www.ScienceTranslationalMedicine.org 6 April 2011 Vol 3 Issue 77 77ra30 3
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 probes Rp1-68d18 (35146316-35329998, covering the CD44 gene and a
portion of the SLC1A2 gene) and Rp11-1148l23 (35294107-35461767,
covering the SLC1A2 gene only) were hybridized to SNU16 cells or normal
lymphoblastoid CCL159 cells. In the control CCL159 cells, we observed a
normal chromosome as indicated by two distinct red and green probe
signals lying adjacent to one another. In contrast, we detected in
SNU16 cells a “split-apart” red-green-red signal, consistentwith an inver-
sion event occurring between these probes (Fig. 2E). Second, we directly
confirmed a CD44/SLC1A2 genomic inversion in SNU16 cells using
long-range genomic PCR, followed by end-sequencing of the PCR
products. Using primers located to CD44 exon 1 and the SLC1A2 first
intron (black arrows in Fig. 2E), we successfully PCR-amplified and
sequence-validated aCD44-SLC1A2 inversion product in SNU16 fusion-
positive cells but not in AGS cells (Fig. 2F). Collectively, these two
alternative methods confirm the presence of a chromosomal inversion
event in SNU16 cells between CD44 and SLC1A2.
Sequence analysis of the CD44-SLC1A2 fusion revealed two distinct
protein translation patterns (fig. S4A). First, translation initiating from
an ATG site in CD44 exon 1 could produce a 65–amino acid protein,
comprising 22 amino acids of CD44 and 43 amino acids of novel se-
quence. Second, protein translation might also initiate from an alternative
ATG site in SLC1A2 exon 2, downstream of the fusion site. Translation
from this alternative ATG would produce a 565–amino acid–long trun-
cated SLC1A2 protein, which is 17 amino acids shorter than the full-
length form, but retaining all functionally relevant domains including
transmembrane helices and symporter domains.
To test whetherCD44-SLC1A2might produce a truncated SLC1A2
protein, we performedWestern blotting using anti-SLC1A2 antibodies on
fusion-positive and -negative GC cells. In SNU16 fusion-positive cells,
we detected a smaller-sized SLC1A2protein compared to fusion-negative
AGS and SNU5 cells (Fig. 2G), consistent with translation initiating from
SLC1A2 exon 2 in SNU16 cells. To further demonstrate that the alter-
native ATG in SLC1A2 exon 2 is capable of initiating protein translation,
we cloned and expressed the full-length CD44-SLC1A2 fusion gene in
HFE145 gastric cells (32). Western blotting analysis confirmed expression
of an immunoreactive SLC1A2 product in CD44-SLC1A2–transfected
HFE145 cells of the expected size (Fig. 2H). This result demonstrates that
the alternative ATG in SLC1A2 exon 2 is sufficient to initiate translation.
CD44-SLC1A2 gene fusion is expressed in primary
gastric cancers
To test whether CD44-SLC1A2 is expressed in clinical specimens, we
screened two of the three original index cases exhibiting SLC1A2 ge-
nomic breakpoints (Fig. 1B). The third index tumor, GC20021048, had
insufficient material available for analysis. CD44-SLC1A2 expression
was detected in tumor GC2000038, but not in corresponding matched
normal tissue (Fig. 3A). This result demonstrates that CD44-SLC1A2
expression can occur in primary tumors and that it is not a “private”
event confined to SNU16 cells alone.
We then performed CD44-SLC1A2 RT-PCR screening in an in-
dependent panel of 43 gastric tumors and matched gastric normal tis-
sues. Two additional tumors that expressed the CD44-SLC1A2 fusion
transcript were identified (Fig. 3B). Similar to the index samples,CD44-
SLC1A2 was not expressed in corresponding matched normal samples
(Fig. 3B, bottom), supporting the cancer-specific nature of the fusion
transcript. Subsequent cloning and sequencing of CD44-SLC1A2
in the fusion-positive tumors revealed that the fusion consistently in-
volved the juxtaposition ofCD44 exon1 to SLC1A2 exon2 (Fig. 3Cand fig.wwwS4B). Analysis of CD44-SLC1A2DNA sequences 3′ to the fusion junc-
tion revealed a silent C/T polymorphism in SLC1A2 exon 4 between
fusion-positive SNU16 and GC980390 (fig. S4C), confirming that the
CD44-SLC1A2 transcripts are indeed distinct entities. This apparent re-
quirement for precise fusionmay be because, among the SLC1A2 exons,
only exon 2 has a suitable alternative start ATG to initiate translation of
a near-complete SLC1A2 protein. Using long-range PCR, we also con-
firmed the presence of CD44/SLC1A2 genomic inversions at the DNA
level in two fusion-positive clinical specimens (GC980390 andGC2000038)
(Fig. 3D). No genomic inversion products were observed in the matched
normal gastric samples, indicating that theCD44/SLC1A2 inversion is a
cancer-associated somatic event.
CD44-SLC1A2 silencing reduces cancer cell proliferation,
invasion, and colony formation
To investigate the functional consequences of inhibiting CD44-SLC1A2
expression, we designed a series of customized small interfering RNAs
(siRNAs) targeting the CD44-SLC1A2 fusion site. Treatment of SNU16
cells with fusion-specific siRNAs successfully silenced CD44-SLC1A2
expression, but did not discernibly alter the independent expression
ofCD44 or SLC1A2 (Fig. 4A). Using SLC1A2 antibodies, we confirmed
silencing at the protein level by both Western blotting and immuno-
fluorescence assays (Fig. 4B and fig. S5). Similar results were obtained
with a second CD44-SLC1A2 targeting siRNA containing overlapping
but distinct sequence (fig. S5). These results confirm the efficacy of the
fusion-specific siRNAs.
SNU16 cells stably silenced with CD44-SLC1A2 siRNAs resulted in
a significant reduction in cell proliferation capacity compared to cellsFig. 3. CD44-SLC1A2 expression in primary GCs. (A) CD44-SLC1A2 RT-PCR
on two index primary GCs (GC980417 and GC2000038) with SLC1A2 ge-
nomic breakpoints (see Fig. 1). GN2000038 is the matched normal sample
to GC2000038. Fusion-positive SNU16 cells are included as a positive con-
trol. (B) CD44-SLC1A2 RT-PCR on 43 gastric tumors and matched NG tissues.
Top: Tumors. Red asterisk, CD44-SLC1A2–expressing tumors (GC980390 and
GC2000639). Bottom: Matched normal tissue. SNU16 is included as a pos-
itive control. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (C)
Sequence of the CD44-SLC1A2 fusion junction in GC2000038. Black bar, fusion
junction. (D) Long-range genomic PCR analysis. Primers used are the same
as in Fig. 2F. GC2000038 and GC980390 are fusion-positive primary GCs.
GN2000038 and GN980390 are matched normal controls..ScienceTranslationalMedicine.org 6 April 2011 Vol 3 Issue 77 77ra30 4
R E S EARCH ART I C L Etreated with scrambled siRNAs (Fig. 4C; P = 0.002, t test). No effects
were observedwhen the fusion-specific siRNAwas applied toAGS cells,
which do not expressCD44-SLC1A2 (fig. S6, A and B). These results sug-
gest thatCD44-SLC1A2may be important for cancer cell proliferation in
GC. To assess the tumorigenicity of SNU16 uponCD44-SLC1A2 knock-
down, we performed colony formation assays. Fusion-silenced cells ex-
hibited a significantly decreased amount of anchorage-independent
growth compared to controls (P = 0.01, Fig. 4D; see fig. S7 for enlarged
figures). We then conductedMatrigel assays to investigate the effects ofwwwCD44-SLC1A2 on cancer cell invasion.CD44-SLC1A2–silenced SNU16
cells also exhibited a decreased level of cell invasion compared with
control cells (Fig. 4E, P = 0.0013), suggesting a potential role for CD44-
SLC1A2 in cell motility and invasion.
To determine whether CD44-SLC1A2 expression might be suffi-
cient to enhance various pro-oncogenic traits, we stably overexpressed
CD44-SLC1A2 in HFE145 NG cells. Compared to control cells, CD44-
SLC1A2–expressingHFE145 cells exhibited enhanced cell proliferation
(P= 0.007), colony formation (P= 0.02), and invasion (P= 7.75 × 10−5).ScienceTranslationalMedicine.or
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 (Fig. 4, F to H). Collectively, these results
suggest that CD44-SLC1A2 is likely re-
quired by GC cells to maintain several
pro-oncogenic traits, such as prolifera-
tion, colony formation, and invasion.
The observation that CD44-SLC1A2
produces an almost full-length SLC1A2
protein lacking only 17 amino acids raises
the possibility thatwild-type SLC1A2might
also be pro-oncogenic. Indeed, silencing of
wild-type SLC1A2 in AGS cells, which are
fusion-negative, resulted in phenotypic ef-
fects comparable to those ofCD44-SLC1A2
silencing in SNU16 cells (fig. S8). In this re-
gard,CD44-SLC1A2may be similar to on-
cogenic fusiongenes such as IgH-Myc and
TMPRSS2-ERG (15, 20), where an essen-
tially full-length pro-oncogenic protein
is placed under the control of a strong tran-
scriptional promoter.
CD44-SLC1A2 silencing significantly
reduces intracellular glutamate
concentrations and sensitizes GC
cells to chemotherapy
One possible mechanism by which CD44-
SLC1A2maycontribute to tumordevelop-
ment is by facilitating glutamate uptake
in GC cells. In many cancers, glutamate
and its related amino acid glutamine have
been shownto functionas importantamino
acids regulating tumor growth and sur-
vival (33, 34). To assess the concentrations
of glutamate in primary GCs, we used a
colorimetric glutamate assay to measure
glutamate in a panel of matched tumor
andnormal pairs (seeMaterials andMeth-
ods). Significantly elevated concentrations
of glutamate were detected in primary tu-
mors compared tomatched normal stom-
ach controls (n = 20; P = 0.038, paired t
test) (Fig. 5A). To test the influence of
CD44-SLC1A2 on intracellular glutamate,
we then compared concentrations of in-
tracellular glutamate across the GC cell
lines.We observed significantly higher ba-
sal glutamate concentrations in CD44-
SLC1A2–expressing SNU16 cells than in
AGS cells (Fig. 5B, P = 0.009). However,Fig. 4. CD44-SLC1A2 fusions enhance cellular proliferation, colony formation, and invasion. (A) CD44-SLC1A2
silencing by fusion-specific siRNA1 (CGCAGAUCGUGCCAACAAUUU).CD44-SLC1A2 expressionwasmeasured
24, 48, and 72 hours after siRNA treatment. CD44: wild-type CD44 expression. CD44 primers were designed to
target exons 3 to 5. SLC1A2: wild-type SLC1A2 expression. SLC1A2 primers were designed to target exon 1.
GAPDHwas used as a loading control. (B) Western blotting. SLC1A2 protein levels weremonitored with anti-
SLC1A2 antibodies. a-Tubulin is used as a loading control. SNU16 cells before (−) and after (+) treatment with
fusion-specific siRNAs. (C to E) Effects of CD44-SLC1A2 knockdown. (C) Proliferation rates of SNU16 cells
before and after CD44-SLC1A2 siRNA treatment. (D) Colony formation assays with SNU16 cells before and
after CD44-SLC1A2 siRNA treatment. (E) Cell invasion assays with SNU16 cells before and after CD44-SLC1A2
siRNA treatment. (F to H) Effects of CD44-SLC1A2 overexpression. (F) Cell proliferation rates of HFE145 cells
before andafterCD44-SLC1A2overexpression. (G) Colony formation assayswithHFE145 cells before andafter
CD44-SLC1A2 overexpression. (H) Cell invasion assays with HFE145 cells before and after CD44-SLC1A2 over-
expression. All experiments were performed in triplicate. P values were computed with Student’s t test. Red
asterisks, P values exceeding the significance threshold (P < 0.05).g 6 April 2011 Vol 3 Issue 77 77ra30 5
R E S EARCH ART I C L EafterCD44-SLC1A2 siRNA treatment, SNU16 glutamate levels were sig-
nificantly reduced compared to scrambled siRNA controls (Fig. 5B, P =
0.01). No significant effects were observed when the fusion siRNAwas
applied to AGS cells (Fig. 5B). This observation suggests that CD44-
SLC1A2may function to regulate intracellular glutamate levels in GC.
Inhibition of glutamate metabolism in cancer cells causes sensitiza-
tion to pharmacologic treatment (35). To test whether CD44-SLC1A2 si-
lencing might sensitize GC cells to drug treatment, we treated control andwww
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 CD44-SLC1A2–silenced SNU16 cells to increasing concentrations of cis-
platin, a chemotherapy reagent commonly used in GC treatment, and
computedGI50s, the drug concentration required to cause 50% growth in-
hibition.We found that SNU16 cells were significantlymore sensitive to
cisplatin afterCD44-SLC1A2 siRNA treatment, with a reduction inGI50
from11.8 to 3.96 mM(P= 1.11× 10−6, Fig. 5C). The sensitization ofCD44-
SLC1A2–silenced cells appears to be specific to cisplatin, because no dif-
ferences between control and silenced cells were observed upon treatment
with 5-fluorouracil (5-FU), another GC chemotherapy agent (fig. S9).
Tumors expressing high SLC1A2 levels are associated
with CD44-SLC1A2 positivity
CD44 is highly expressed inmany cancers including GC (36). One con-
sequence of the CD44-SLC1A2 fusion might thus be to place SLC1A2
under the regulatory control of CD44 promoter elements, causing high
amounts of SLC1A2 expression in tumors. If this were true, tumors
expressing high SLC1A2 levels should also tend to be CD44-SLC1A2–
positive. To explore this possibility, we queried a previously described
gene expression database of 197GCs to identify tumors expressing high
SLC1A2 levels (37). We screened 15 GCs from the top 15% of SLC1A2-
overexpressing tumors for CD44-SLC1A2 expression. Among the 15
tumors, five GCs expressed the CD44-SLC1A2 fusion transcript (Fig.
6, blue crosses), and none of the matched adjacent normal tissues ex-
pressedCD44-SLC1A2 (Fig. 6). Thus, whereas the rate ofCD44-SLC1A2
positivity in an unselected patient cohort is low (1 to 2%), the CD44-
SLC1A2 positivity rate is elevated in this selected subpopulation (33%,
5 of 15 tumors). This result is consistent with the CD44-SLC1A2 fusion
causing the transcriptional up-regulation of SLC1A2. In CD44-SLC1A2–
negative tumors, high SLC1A2 levels may be due to alternative mecha-
nisms, such as focal genomic amplification, fusion to other partners, and
epidermal growth factor (EGF) or mammalian target of rapamycin
(mTOR)/Akt signaling (38, 39).
An unsupervised clustering analysis of the 197 gastric tumor gene ex-
pression profiles revealed that most of high SLC1A2–expressing tumors
tended to cluster together (>75%), suggesting thathighSLC1A2 expressionD
ow
nl
oa
de
d 
frFig. 5. CD44-SLC1A2 regulates intracellular glutamate levels and sensitizes cells
to cisplatin. (A) Glutamate concentrations in primaryGCs compared tomatched
normal controls. X axis, 20 cancer/normal pairs. P values were computed with a
paired t test comparing each tumor to its matched normal control. (B) Gluta-
mate concentrations in GC cells before and afterCD44-SLC1A2 siRNA treatment.
All experiments were performed in triplicate. (C) Cisplatin sensitivity of SNU16
cellswithandwithout stableCD44-SLC1A2 siRNAsilencing.All experimentswere
performed in triplicate. P values were computed at 10 mM cisplatin. P values for
(B) and (C) were computed with a t test. Red asterisk, P values exceeding the
significance threshold (P < 0.05).Fig. 6. CD44-SLC1A2–positive tumors are associated with high SLC1A2 ex-
pression. Graph: SLC1A2mRNAexpression in 197GCs. Gene expression data
weremedian-centered. The top 15% of high SLC1A2–expressing tumors are
shown in red. Inset: RT-PCR screening of CD44-SLC1A2 in the top 15% of
high SLC1A2–expressingGCs andmatching 15NG tissues. GAPDHwas used
as a loading control. Blue crosses, samples expressing CD44-SLC1A2. SNU16
cells (S16) were included as a positive control. The smaller band of 200 bp
was sequenced and identified to be nonspecific (ns)..ScienceTranslationalMedicine.org 6 April 2011 Vol 3 Issue 77 77ra30 6
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 may define a distinct molecular subgroup of GC (fig. S10). To identify
predominant biological themes associated with this molecular subgroup,
we performed gene ontology (GO) analysis on a 710-gene “SLC1A2 sig-
nature,” generatedby comparing the top15%of high SLC1A2–expressing
tumors against the bottom 15% [Wilcoxon signed rank test, false discov-
ery rate (FDR) = 0.005]. Genes expressed in high SLC1A2–expressing tu-
morswere associatedwith ribosomal biosynthesis and protein translation
(corrected P = 5.12 × 10−33, Fisher’s test; table S2). These results suggest
that tumors expressing high SLC1A2 levels, by either CD44 fusion or
alternative mechanisms, may comprise a distinct subclass of GC.
CD44-SLC1A2 expression can occur independently
of 11p13 amplification
Although CD44-SLC1A2 was initially identified in tumors exhibiting
11p13 amplification (Fig. 1B), 11p13 amplification may not be an ab-
solute prerequisite for CD44-SLC1A2 fusion expression. To investigate
the relationship between 11p13 genomic amplification and CD44-
SLC1A2 expression, we analyzed seven fusion-positive tumors using
Affymetrix SNP6 arrays. Of seven fusion-positive tumors, two tumors
(GC980390 and GC990172) exhibited evidence of 11p13 genomic
amplification, whereas the other five did not (fig. S11). This finding
demonstrates thatCD44-SLC1A2 expression can be observed in tumors
independent of 11p13 genomic amplification. To further investigate the
notion that 11p13 amplification andCD44-SLC1A2 gene fusion are dis-
tinct events, we compared CD44 and SLC1A2 expression across 45 gas-
tric tumors, including (i) 11p13-nonamplified samples (32 samples), (ii)
11p13-amplified but fusion-negative samples (6 samples), and (iii)CD44-
SLC1A2 fusion-positive samples (7 samples). The rate of 11p13 amplifica-
tion in this series (~17%) is similar to frequencies previously reported in
the literature (40). It is important to note that in this experiment, the ex-
pressionmeasurements were inferred using U133P2 Affymetrix microar-
ray probes, which target the 3′ ends of genes. Compared to nonamplified
samples, fusion-positive samples exhibited significantly increased 3′
SLC1A2 gene expression (P = 0.004), but 11p13-amplified samples
did not (P = 0.86) (fig. S11A). These findings suggest that high SLC1A2
expression levels may be driven more by fusion events rather than by
generalized 11p13 amplification. The one exceptionwas a samplewith a
high-level focal 11p13 amplification (GC980417); in this tumor, SLC1A2
was highly expressed (fig. S11A). Intriguingly, unlike SLC1A2, a very dif-
ferent scenario was observed for CD44. Specifically, although CD44 3′
transcripts were significantly overexpressed in 11p13-amplified tumors
(P = 0.016), they were significantly underexpressed in fusion-positive tu-
mors (P = 0.006) (fig. S11B). We speculate that this latter finding may
be due to the CD44/SLC1A2 genomic inversion decoupling the 3′ end
of the CD44 gene (the region detected by the Affymetrix array) from
the endogenous CD44 promoter. Additional evidence of this decou-
pling was obtained in a real-time PCR analysis measuring SLC1A2 ex-
on 1, where, unlike the 3′ SLC1A2 transcripts, SLC1A2 exon 1 (which
is not part of the CD44-SLC1A2 fusion) was not observed to be highly
expressed relative to nonamplified samples in fusion-positive samples
(fig. S11, C and D).DISCUSSION
The cancer-specific nature of fusion genes has earned them an impor-
tant place inmany translational cancer research applications, including
molecular subtyping, monitoring for disease relapse, and as drug tar-wwwgets. In pediatric acute lymphoblastic leukemia (ALL), expression of
AML-ETO and PML-RAR is routinely used to diagnose particular clin-
ical subtypes (17), and treatment of CML has been revolutionized by
imatinib, an inhibitor of the BCR-ABL fusion gene (18). Along with
AGTRAP-BRAF fusions (22), CD44-SLC1A2 represents another recur-
rent gene fusion identified in a major GI cancer, providing further ev-
idence for the existence of this important class ofmolecular aberrations
in GI malignancies.
Here, we used GBA to uncover the existence ofCD44-SLC1A2 gene
fusions in GC. Notably, although GBA has been previously used for
fusion gene discovery in leukemia (27, 41), our study demonstrates that
this approach can also highlight potential fusion genes in solid epithe-
lial tumors. Among genes exhibiting genomic breakpoints, we priori-
tized genes for study based on their rate of recurrence in multiple
samples and occurrence in a cell line to serve as an experimentalmodel.
Using these two criteria, we nominated only two genes: SLC1A2 and
ZNF1A3. We note that GBA does come with a few caveats, because
fusion events arising from balanced chromosomal rearrangements
would not alter overall copy number levels and are unlikely to be de-
tected. However, GBA has the advantage of being readily applicable to
aCGH data, for which there are already numerous large-scale data sets
readily available in the public domain (42). Revisiting these data sets
may identify additional genes recurrently targeted by genomic break-
points in solid cancers.
The identification of SLC1A2, a glutamate transporter, as a fusion
gene participant is notable. To date, the vast majority of known onco-
genic fusion events have largely involved transcription factors (for ex-
ample,Myc andRAR) or kinases (for example,BCR-ABL) (15–17). The
discovery of CD44-SLC1A2 raises the intriguing possibility that onco-
genic gene fusions may also target genes involved in cancer metabo-
lism. Specifically, the CD44-SLC1A2 gene fusion is predicted to
produce a slightly truncated SLC1A2 protein that retains most of the
key protein domains required for glutamate transporter fusion, and
may function to facilitate glutamate accumulation in GC cells. A sub-
stantial body of evidence has implicated glutamate and glutamine as
critical amino acids necessary for the maintenance and elaboration
of cancer-specific traits (43). For example, glutamate and glutamine
have been shown to regulate tumor growth and oncogenic signals such
as mTOR (44). The requirement of cancer cells for glutamate may also
be related to the Warburg effect, a universal feature of cancer cells
where they exhibit overactive glycolysis because of a deficiency in
channeling glycolytic metabolites into the tricarboxylic acid (TCA)
cycle for adenosine triphosphate (ATP) generation. Glutamate may
provide cancer cells with an alternative route of ATP production be-
cause intracellular glutamate and glutamine can also be converted into
a-ketoglutarate, a TCA cycle intermediate (45). Glutamate levels have
been shown to be elevated in many cancers, and in our study, we con-
firmed that glutamate levels are also elevated in gastric tumors com-
pared to normal stomach, consistent with a previous report (46).
The absolute rate of CD44-SLC1A2 positivity was relatively low in
this study (1 to 2%); however, analyses of larger GC patient cohorts will
be required to determine the true CD44-SLC1A2 positivity rate. Never-
theless, we note that even low-frequency events in cancer can prove
therapeutically useful, as shown by EML4-ALK fusions in lung cancer
(1 to 5%) (21) andRAF fusions in gastric,melanoma, and prostate cancers
(22). As a cell membrane–bound receptor, CD44-SLC1A2 may prove
amenable to targeting using either small molecules or therapeutic anti-
bodies. Several of the CD44-SLC1A2–positive GCs in our study also.ScienceTranslationalMedicine.org 6 April 2011 Vol 3 Issue 77 77ra30 7
R E S EARCH ART I C L Eexhibited focal amplifications in genes specifically related toRTK(receptor
tyrosine kinase)/RAS/MAPK (mitogen-activated protein kinase) signal-
ing, including SNU16 (FGFR2), GC2000114 (MET), GC2000639 (KRAS),
and GC980390 (ERBB2). CD44-SLC1A2 may collaborate with these
canonical oncogenes to facilitate MAPK signaling in GC. Beyond its
effects in cancer development, targetingCD44-SLC1A2 in fusion-positive
tumors may also represent a promising avenue for sensitizing GCs to
commonly used standard-of-care chemotherapies, because silencing
CD44-SLC1A2 was sufficient to cause a significant sensitization of GC
cells to cisplatin in vitro. It will be interesting to evaluate the potential of
CD44-SLC1A2 as a potential drug target, and determining exactly how
this gene fusion, and possibly other glutamate-related transporters,
might contribute to GC development by establishing a metabolic envi-
ronment favoring oncogenesis. 
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 MATERIALS AND METHODS
Primary tumors and cell lines
Primary gastric tumors were obtained from the SingHealth Tissue Re-
pository, an institutional resource of National Cancer Centre of Singapore
and SingaporeGeneralHospital. All patient sampleswere obtainedwith
informed patient consent and approvals from Institutional Review
Boards and Ethics Committees. GC cell lines AGS, KATO III, SNU1,
SNU16, N87, and Hs746T were purchased from the American Type
Culture Collection. AZ521, Ist1, TMK1, MKN1, MKN7, MKN28,
MKN45,MKN74, Fu97, and IM95 cells were obtained from the Japan
Health Science Research Resource Bank. SCH cells were provided by
Y. Ito (Cancer Sciences Institute of Singapore). YCC cells were a gift
from S.-Y. Rha (Yonsei Cancer Center, South Korea).
RNA and DNA extraction
Genomic DNA from samples was extracted with a Qiagen Blood and
Cell Culture DNA extraction kit. Total RNA was extracted with RNA
extraction reagents (Qiagen). Both RNAs and DNAs were quantitated
with either NanoDrop ND-1000 (NanoDrop Technologies) or Agilent
Bioanalyzer 2100 (Agilent Technologies).
GBA
GBAwas performed on a panel of 106 primary tumors and 27 cell lines
withAgilent 244KHumanGenomeMicroarrays (Agilent Technologies).
Sample labeling and hybridizations were performed according to the
manufacturer’s instructions. Tumor and control genomicDNAs (human
spleen DNA) were labeled with Cy3-dUTP (deoxyuridine triphosphate)
and Cy5-dUTP, respectively. Hybridized slides were scanned on an
Agilent DNA Microarray Scanner (Agilent Technologies), and images
were extractedwithAgilent Feature Extraction software. Datawere ana-
lyzed with Agilent CGH Analytics software (v.3.5) using a Z-score al-
gorithm with a threshold of 2.0 and a one-point window to identify
genomic breakpoints.
FISH
SNU16 interphase and metaphase cell pellets were prepared for FISH
analysis by standard hypotonic treatment and fixation after colcemid
exposure (10 mg/ml) for 2 hours. Before hybridization, cells were pre-
treatedwith pepsin (100mg/ml) (Sigma) and 0.01MHCl at 37°C (5min),
fixed in 1% formaldehyde (Sigma) (10min), anddehydrated in an ethanol
series. Fosmid and bacterial artificial chromosome (BAC) probes werewwwobtained from BACPAC Resource Center (CHORI) and grown follow-
ing vendor instructions. DNA was extracted with Nucleobond PC500
(Macherey-Nagel), followed by labeling with either biotin-16–dUTP
(Roche) or digoxigenin-11–dUTP (Roche) with an Enzo Nick Transla-
tion DNA labeling system. About 20 ng of each probe was used per hy-
bridization in addition to 10 mg of Cot-1 DNA (Invitrogen). The slide
and probe mixes were co-denatured on a hot plate set at 75°C and hy-
bridized overnight at 37°C. Posthybridizationwasheswere performed at
45°C in 50% prewarmed formamide/2× SSC solution (twice), followed
by two washes in 2× SSC (twice). Slides were blocked with blocking re-
agent (Roche), followed by incubation with avidin-conjugated fluores-
cein isothiocyanate (FITC) (Roche) and anti–digoxigenin-rhodamine
(Roche), respectively. 4′,6-Diamidino-2-phenylindole (DAPI) counter-
stain (Vector Laboratories) was then used to stain the nuclei to enable
visualization. Slides weremounted with Vectashield (Vector Laboratories).
Fluorescence images were captured with a 60× objective using a cooled
charge-coupled device (CCD) camera attached to a Nikon fluorescence
microscope. Automated image capture was performed with ISIS soft-
ware (Metasystems).
RLM-RACE
5′ RACE. RLM-RACE was performed with the FirstChoice RLM-
RACE kit (Applied Biosystems). Total RNA (10 mg) was first treated
with calf intestinal alkaline phosphatase (CIP) to remove 5′ phos-
phate groups, followed by tobacco acid pyrophosphatase to remove
5′ cap structures. After RNA linker ligation, mRNA transcripts were
reverse-transcribed with Moloney murine leukemia virus (MMLV)
reverse transcriptase. To amplify first-strand cDNAs, we performed
outer 5′ PCR using 5′ RACE outer primers and a SLC1A2 exon 3
primer (ACACACTGCTCCCAGGATGA) with SuperTaq Plus poly-
merase (Applied Biosystems). Subsequently, inner 5′ PCR was per-
formed with a 5′ RACE inner primer (provided in kit) and a
SLC1A2 exon 2 primer (AGCCAAGATGACTGTCGTGCATTC).
After gel electrophoresis, PCR bands of interest were excised and
cloned into pCR 4-TOPO (Invitrogen) vectors. Purified plasmid
DNAs were sequenced bidirectionally on an ABI 3730 automated se-
quencer (Applied Biosystems). A minimum of five independent col-
onies were sequenced in each experiment.
3′ RACE. RLM-RACE was performed with the FirstChoice RLM-
RACE kit (Applied Biosystems). Total RNA (1 mg) was reverse-
transcribed with a 3′RACE adaptor and reverse transcriptase provided
in the kit. To amplify first-strand cDNAs, we performed outer 3′ PCR
using 3′ RACE outer primers and a SLC1A2 exon 1 primer (TTG-
AGGCGCTAAAGGGCTTACC) with SuperTaq Plus polymerase
(Applied Biosystems). Subsequently, inner 3′ PCRwas performed with
a 3′ RACE inner primer (provided in kit) and a separate SLC1A2 exon
1 primer (CAGACCATGGCATCTACGGAAGG). After gel electro-
phoresis, PCR bands of interest were excised and cloned into PCR
4-TOPO (Invitrogen) vectors. Purified plasmid DNAs were sequenced
bidirectionally on an ABI 3730 automated sequencer (Applied Biosys-
tems). A minimum of five independent colonies were sequenced in
each experiment.
Semiquantitative and quantitative RT-PCR
Semiquantitative RT-PCR. GC RNAs were reverse-transcribed
by SuperScript II reverse transcriptase enzyme with oligo-dT (T18)
primers (Invitrogen). To detect CD44-SLC1A2, we performed RT-
PCR using forward primers to CD44 exon 1 (CCATGGACAAGT-.ScienceTranslationalMedicine.org 6 April 2011 Vol 3 Issue 77 77ra30 8
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 TTTGGTGGCA) and reverse primers to SLC1A2 exon 3 (GTA-
TATCCCCTGGGAAGGCT), exon 4 (CAGCTGCTTCTTGAGCT-
TGGGA), exon 5 (AAGCAGGCTTGGACAAGGTT), or exon 6
(CTCGTTCAACAGAGAGACAACAGC). Products were resolved
by gel electrophoresis, and bands of interest were excised and cloned
for subsequent analysis. To evaluate wild-type CD44 and SLC1A2
expression independently of CD44-SLC1A2, we used CD44 primers
targeting exons 3 to 5, and SLC1A2 primers targeting exon 1.
CD44-SLC1A2 RT-PCR involving clinical specimens (Fig. 3) was per-
formed in an unselected cohort of GC patients. Reactions were re-
peated a minimum of three independent times.
Quantitative RT-PCR. SNU16 GC cells lines and nine primary
gastric tumors were selected for quantitative RT-PCR (qRT-PCR)
analysis. T1, T2, and T3 were group 1 gastric tumors that are
11p13 amplification–negative and fusion-negative; T4, T5, and T6
are group 2 tumors that are 11p13-amplified but do not express
CD44-SLC1A2; T7, T8, and T9 were group 3 tumors expressing
CD44-SLC1A2 but are 11p13-nonamplified. Briefly, 2 mg of RNA
was reverse-transcribed by SuperScript III reverse transcriptase en-
zyme with oligo-dT (T18) primers (Invitrogen). qRT-PCR was per-
formed with QuantiFast SYBR Green PCR kit (Qiagen) following the
manufacturer’s instructions. Primers used were the following: fusion
forward primer targeting CD44 exon 1 (TTCGGTCCGCCATCCT-
CGTC) and reverse primer targeting SLC1A2 exon 2 (CACTTC-
CACCTGCTTGGGCA); SLC1A2 exon 1 forward primer
(GCCCGTTGAGGCGCTAAAGG) and reverse primer (AGCAC-
TATCCGGCAGCTGTG); and GAPDH forward primer
(CCACCCAGAAGACTGTGGATGG) and reverse primer (CACT-
GACACGTTGGCAGTGG). Samples were analyzed with Applied
Biosystems 7900HT system.
DNA sequencing
Purified PCR products were sequenced in forward and reverse direc-
tions with the ABI PRISMBigDye Terminator Cycle Sequencing Ready
Reaction kit (version 3) andABI PRISM3730Genetic Analyzer (Applied
Biosystems). Chromatograms were analyzed by SeqScape V2.5 and
manual review.
Fiber-FISH
SNU16 cells and control cells (normal lymphoblastoid CCL159) were
grown in RPMI 1640 enriched with 15% fetal bovine serum (FBS), 1%
penicillin-streptomycin, and 1% L-glutamine. Each cell suspension (2
to 3ml) was centrifuged at 1200 rpm for 12min and thenwashedwith
6 ml of phosphate-buffered saline (PBS) twice. Pellets were diluted
with PBS to a final concentration of about 2 × 104 to 3 × 104/ml. Each
cell suspension (10 ml) was spread on a poly-L-lysine (Sigma)–coated
slide, air-dried, and then fitted into a Cadenza coverslip according to
the manufacturer’s recommendations (Thermo Shandon). Freshly
made lysis solution (150 ml) (5:2 70 mM NaOH/absolute ethanol)
was applied to the slides, followed by 150 ml of 96% ethanol. Slides were
air-dried at room temperature, treated with 3:1 acetic acid/ethanol fix-
ative for 5min, and dehydrated in ethanol series (70, 90, and 100%) for
3 min each. The FISH procedure was then applied.
Long-range genomic PCR
CD44/SLC1A2 chromosomal inversions were detected with a long-
range PCR kit (Qiagen) following the manufacturer’s instructions.
Reactions were performed with a forward primer at CD44 exonwww1 (GAAGAAAGCCAGTGCGTCTC, positive strand) and a reverse
primer at SLC1A2 intron 1 in the minimal breakpoint region
(GAGGGCTGTCCTTAACGCCTAGC, negative strand). Exper-
iments were repeated a minimum of three independent times.
Western blotting
Cells were harvested in lysis buffer [10 mM tris-Cl (pH 7.5), 150 mM
NaCl, 1% Triton X-114] for 1 hour at 4°C and centrifuged at 800g.
Supernatants were incubated at 30°C for 5 to 10 min and further cen-
trifuged at 300g at room temperature. Western blotting was performed
on membrane fractions with the following antibodies and dilutions:
SLC1A2/EAAT2 (1:500; Cell Signaling Technology) and a-tubulin
(1:2000; Cell Signaling Technology). Experiments were repeated a
minimum of three independent times.
Immunofluorescence staining
Cells were fixed with 3.7% formaldehyde followed by permeabilization
with 0.1% Triton X-100. After three washes with 1× PBS, cells were
blockedwith 1% bovine serum albumin (BSA). Subsequently, cells were
incubatedwith primary SLC1A2 antibodies (Cell SignalingTechnology)
for 2 hours followed by 2-hour secondary antibody (Sigma) incubation.
Images were taken with a Nikon Eclipse TE2000-U microscope.
CD44-SLC1A2 siRNA transfections and overexpression
GC cells were transfected with either specific siRNAs targeted to the
CD44-SLC1A2 fusion site (100 nM, custom siRNA siGENOME with
SMART selection, Dharmacon) or negative control scrambled siRNAs
with siPORTNeoFX transfection reagent (Applied Biosystems) inOpti-
MEM (Invitrogen) following the manufacturer’s protocol. After 24, 48,
and 72 hours of siRNA treatment, cells were subjected for downstream
analysis. For wild-type SLC1A2 siRNAs, GC cells were transfected with
specific nonoverlapping siRNAs targeted to either SLC1A2 exon 1 or
SLC1A2 downstream regions (100 nM, custom siRNA siGENOME
with SMART selection, Dharmacon) or negative control scrambled
siRNAswith siPORTNeoFX transfection reagent (Applied Biosystems)
in Opti-MEM (Invitrogen) following the manufacturer’s protocol. For
overexpression studies, the full-length coding regions of CD44-SLC1A2
cDNAwere inserted into thepEGFP-N1vector. Control vectors or fusion
green fluorescent protein (GFP) vectors were introduced into HFE145
cells, and stable transfectants were selected with G418 (stable overexpres-
sion) or puromycin (stable knockdown) for 4 weeks.
Cell proliferation assay and invasion assays
Cell proliferation assays were performed with a CellTiter96 Aqueous
Nonradioactive Cell Proliferation Assay kit (Promega) following the
manufacturer’s instructions, and the plates were measured with a Perkin-
Elmer plate reader. Cell invasion assays were performed with Biocoat
Matrigel invasion chambers with 8-mmpore filter inserts (BDBiosciences).
Forty-eight hours after transfection, 5 × 104 cells were transferred to the
upper Matrigel chamber in 500 ml of serum-free medium and incubated
for 24hours. Invading cellswere countedwith lightmicroscopy. Each assay
was performed in triplicate, and the results were averaged over three
independent experiments.
Colony formation assays
Base layers of 0.5% gum agar in 1× McCoy’s 5A and 10% FBS were
poured into six-well plates and allowed to harden at 4°C.After 48 hours
of siRNA transfection, 50,000 cells per well were seeded in complete.ScienceTranslationalMedicine.org 6 April 2011 Vol 3 Issue 77 77ra30 9
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 medium plus agar mixture at 42°C and seeded on top of the solidified
base layer. Plates were incubated at 37°C for 3 to 4 weeks, during which
plates were fed dropwise with complete medium. After 3 to 4 weeks,
plates were photographed with the Kodak GL 200 System (EpiWhite
illumination). Each assay was performed in triplicate, and the results
were averaged over three independent experiments.
Glutamate assays and drug treatments
GC cells and primary tissues were lysed in glutamate assay buffer, and
glutamate concentrations were determinedwith a Glutamate Assay Kit
(BioVision). Briefly, to each cellular lysate, a vendor-provided gluta-
mate enzyme mix was added, which recognizes glutamate as a specific
substrate, leading to proportional color development. For cisplatin
treatments, cells were seeded into 96-well plates after siRNA transfec-
tion. Subsequently, cisplatin or 5-FU at increasing dosages (0 to 1mM)
was added to respective wells. Cells were subjected to MTS [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium] proliferation assays after 48 hours of drug treatment.
Each assay was performed in triplicate, and the results were averaged
over three independent experiments.
Copy number analysis (Affymetrix)
Affymetrix SNP6 arrays were processed with Affymetrix GTC 4.0
software, and tumor profiles were normalized against a matched
normal reference. The data were visualized with Nexus 5.0 software
(Biodiscovery). A rank segmentation algorithm, a variation of the seg-
mentation method based on circular binary segmentation, was used to
segment the copy number data across the genome.
Gene expression analysis
Gene expression data are available from theGene ExpressionOmnibus
database under accession number GSE15460. Gene expression profiles
(Affymetrix U133P2 arrays) were normalized with the MAS5 algorithm.
Comparisons between CD44 and SLC1A2 expression values were per-
formedon a subset of 45 samples forwhich gene expression, copynumber
information, and CD44-SLC1A2 gene fusion status were available.
Unsupervised clustering was based on all probe sets after removing
the bottom 25% of probes with the lowest interquantile range. Hierar-
chical clustering andWilcoxon signed rank tests were performedwith R
software 2.9.0. FDR q-value calculations were calculated with the R
package “qvalue.”GOanalysis was performedwith theDAVIDdatabase.
Statistical analysis
Experiments were assessed by Student’s unpaired t test, with the excep-
tion of the tumor/normal glutamate measurements, where a paired t
test was used. P values of <0.05 were considered statistically significant.SUPPLEMENTARY MATERIAL
www.sciencetranslationalmedicine.org/cgi/content/full/3/77/77ra30/DC1
Fig. S1. MYC, ERBB2, RAB23, and PTEN genomic aberrations in SNU16, N87, HS746T, and TMK1
cells detected by aCGH.
Fig. S2. 3′ RACE and full-length CD44-SLC1A2 expression in SNU16 cells.
Fig. S3. Chromosomal inversion model of CD44-SLC1A2 gene fusion.
Fig. S4. Predicted protein structure of CD44-SLC1A2 and expression in primary GCs.
Fig. S5. Silencing CD44-SLC1A2 with a second fusion-specific siRNA inhibits cellular prolifera-
tion, invasion, and colony formation.
Fig. S6. CD44-SLC1A2 silencing does not affect AGS cells.
Fig. S7. Soft agar assays with two fusion-specific siRNAs.www.SFig. S8. Reduction of cellular proliferation in fusion-negative AGS cells after silencing of wild-
type SLC1A2.
Fig. S9. CD44-SLC1A2 knockdown does not sensitize cells to 5-fluorouracil chemotherapy.
Fig. S10. Unsupervised clustering of GC expression profiles reveals clustering of high SLC1A2–
expressing tumors.
Fig. S11. 11p13 copy number status in CD44-SLC1A2–expressing samples.
Fig. S12. CD44 and SLC1A2 expression levels of 11p13-nonamplified, 11p13-amplified, and
fusion-positive samples.
Table S1. Gene exhibiting genomic breakpoints.
Table S2. Gene ontology analysis of high SLC1A2–expressing tumors.
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